Lisata Therapeutics (LSTA) Company Overview

Lisata Therapeutics Inc (NASDAQ:LSTA) joined Proactive to discuss the latest updates from the compay's pancreatic cancer trials. The company recently announced preliminary results from its Phase 2ASCEND  trial at the ASCO Gastrointestinal conference.

Lisata Therapeutics Inc (NASDAQ:LSTA) and WARPNINE have announced promising preliminary results from their Phase 1b/2a iLSTA trial, which is evaluating Lisata's investigational drug certepetide in combination with standard-of-care chemotherapy and immunotherapy for locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC). The iLSTA trial is being conducted at St John of God Subiaco Hospital in Western Australia, involving 30 patients divided into three treatment cohorts.

Lisata Therapeutics Inc (NASDAQ:LSTA) has reported encouraging preliminary data for Cohort A of its ongoing ASCEND Phase 2 trial. The trial, conducted across 25 sites in Australia and New Zealand, is evaluating the efficacy of Lisata's novel therapy certepetide in combination with standard-of-care chemotherapy for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC), an aggressive form of pancreatic cancer.

BASKING RIDGE, N.J., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will present a corporate overview at the upcoming Sequire Investor Summit being held January 21-23, 2025 in San Juan, Puerto Rico.

Lisata Therapeutics Inc (NASDAQ:LSTA) shares were reacting positively this week after the company announced further developments for its lead investigational drug candidate, certepetide.  The company announced the completion of patient enrollment in the Phase 1b/2a CENDIFOX trial, evaluating its iRGD cyclic peptide, certepetide, with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers.

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has completed patient enrollment in all three cohorts of its Phase 1b/2a CENDIFOX trial evaluating the safety and efficacy of Lisata's investigational drug certepetide in combination with FOLFIRINOX-based therapies for pancreatic, colon and appendiceal cancers. Certepetide is a cyclic peptide designed to enhance the delivery of anti-cancer drugs by activating a unique pathway that helps them target and penetrate solid tumors more effectively.

Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colon and appendiceal cancers Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colon and appendiceal cancers

Lisata Therapeutics Inc (NASDAQ:LSTA) has been awarded the title of ‘Specialized BioTherapeutics Company of the Year' at the 2024 BioTech Breakthrough Awards. The company said it was recognized for its unique approach to addressing the unmet medical needs of patients with advanced solid tumors, particularly through its proprietary CendR Platform technology which enhances the delivery and efficacy of anti-cancer treatments by targeting the tumor microenvironment.

Award recognizes Lisata's data-driven approach and innovative therapies designed to address the unmet medical needs of patients with advanced solid tumors